Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Endocrine disorders – page 26

  • 504 clinical trials
  • 189 recruiting
  • 213 conditions
  • 25 countries

Conditions in this area

213 conditions with trials, the busiest first

Type 2 diabetes mellitus85Type 1 diabetes mellitus41Endocrine ophthalmopathy26Neuroblastoma26Obesity24Diabetes mellitus21Neuroendocrine tumour19Overweight18Gastroenteropancreatic neuroendocrine tumour disease16Diabetic neuropathy13Diabetic retinal oedema13Diabetic foot12Myotonic dystrophy12Adrenogenital syndrome11Neuroendocrine carcinoma11Thyroid cancer11Graves' disease10Hypoparathyroidism9Acromegaly8Adrenoleukodystrophy8Chronic kidney disease8Glucose tolerance impaired7Pancreatic neuroendocrine tumour7Adrenocortical carcinoma6+189

Clinical trials in Endocrine disorders

504 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

504 clinical trials

Endocrine ophthalmopathy

Not recruiting

Study of VRDN-001 compared to placebo to evaluate safety and effectiveness in adults with chronic thyroid eye disease

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:Viridian Therapeutics Inc.

Type 2 diabetes mellitus

Not recruiting

Study of LY3457263 compared to placebo in adults with type 2 diabetes who are taking semaglutide or tirzepatide but have not reached their blood sugar goals

Investigational
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Tirzepatide
  • Sponsor:Eli Lilly & Co.

Type 2 diabetes mellitus

Not recruiting

Study comparing RO7795081 and semaglutide with placebo in adults with type 2 diabetes mellitus

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:RO7795081
  • Sponsor:F. Hoffmann-La Roche AG

Type 1 diabetes mellitus

Not recruiting

Comparing weekly insulin icodec and daily insulin glargine with insulin aspart in adults with type 1 diabetes: a 26-week study of blood sugar control

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Insulin Glargine
  • Sponsor:Novo Nordisk A/S

Adrenoleukodystrophy

Not recruiting

Study of drug interactions between leriglitazone, gemfibrozil, itraconazole, and carbamazepine and food effects in healthy male volunteers for adrenoleukodystrophy treatment

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · Healthy volunteers
  • Substances:Carbamazepine
  • Sponsor:Minoryx Therapeutics S.L.

Acromegaly

Not recruiting

Study of ALXN2420 with somatostatin analogs for adults with acromegaly to evaluate effectiveness in lowering IGF-1 levels

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:ALXN2420
  • Sponsor:Alexion Pharmaceuticals Inc.

Primary hyperaldosteronism

Not recruiting

Study of baxdrostat compared to placebo to treat adults with primary aldosteronism

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Baxdrostat
  • Sponsor:AstraZeneca AB

Type 2 diabetes mellitus

Not recruiting

Study on the Effects of Ertugliflozin and Semaglutide on Heart Health in Patients with Type 2 Diabetes

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Canagliflozin
  • Sponsor:Universita Cattolica Del Sacro Cuore

Diabetic retinal oedema

Not recruiting

Study on the Effectiveness and Safety of EYE103 Compared to Ranibizumab for Patients with Diabetic Macular Edema

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:EYE103
  • Sponsor:Eyebiotech Limited

Metabolic syndrome

Not recruiting

Study on the Effects of Roxadustat and Placebo on Cardiovascular Risk Factors and Metabolic Syndrome in Patients

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · Healthy volunteers
  • Substances:Placebo
  • Sponsor:Pohjois-Pohjanmaan hyvinvointialue

Diabetic nephropathy

Not recruiting

Study on Hyperpolarized [1-13C]Pyruvate and Meglumine Gadoterate for Patients with Diabetic Kidney Disease

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Meglumine Gadoterate
  • Sponsor:Aarhus University

Type 2 diabetes mellitus

Not recruiting

Study on Fecal Microbiota Transfer for Better Diabetes Control in Adults with Type 2 Diabetes After Bariatric Surgery

Investigational
Countries:FranceFrance
  • Participants:18–64 years · Healthy volunteers
  • Substances:Placebo
  • Sponsor:Assistance Publique Hopitaux De Paris

Substances studied in this area

The therapies tested most often in Endocrine disorders trials.

Semaglutide48 clinical trialsDapagliflozin21 clinical trialsEmpagliflozin14 clinical trialsMetformin Hydrochloride13 clinical trialsMetformin12 clinical trialsSodium Chloride12 clinical trialsCisplatin11 clinical trialsEtoposide11 clinical trialsLutetium (177LU) oxodotreotide11 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.